Trial Profile

Phase I/II Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niraparib (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms NIVIX

Most Recent Events

19 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Nov 2023.
07 Dec 2022 Status changed from recruiting to suspended.
22 Apr 2021 Planned number of patients changed from 20 to 24.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com